Montelukast Sandoz

Montelukast, the active ingredient in Montelukast Sandoz, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in appropriate patients.

GNH USA supplies Montelukast Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and allergic symptoms.

- Asthma: provides maintenance therapy that reduces frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Sore throat: mild irritation of the pharynx. - Diarrhea: loose stools. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Mood changes: depression, anxiety, or suicidal thoughts. - Hepatic enzyme elevation: potential liver function abnormalities. - Stevens‑Johnson syndrome: severe skin reaction. - Severe bronchospasm: paradoxical worsening of breathing. - Blood dyscrasias: rare hematologic abnormalities.

Before initiating therapy, consider the following safety measures.

- Pregnancy: consult a healthcare provider; safety data are limited. - Breastfeeding: weigh potential benefits against risks. - Liver impairment: use with caution; monitor hepatic function. - Enzyme‑inducing drugs: phenobarbital or rifampin may lower effectiveness. - Not for acute attacks: do not replace rescue inhalers during sudden asthma worsening. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines; review the following.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma concentrations. - Rifampin: can decrease therapeutic effect. - Ketoconazole: may increase montelukast levels, raising risk of side effects.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR; monitor coagulation. - Theophylline: may raise plasma concentrations. - Beta‑agonists: additive bronchodilation; monitor respiratory response.